Stimulation of the amino acid transporter SLC6A19 by JAK2

Biochemical and Biophysical Research Communications

Volumn 414, Issue 3, 2011, Pages 456-461

  Bhavsar, Shefalee K ^a   Hosseinzadeh, Zohreh ^a   Merches, Katja ^a   Gu, Shuchen ^a   Bröer, Stefan ^b   Lang, Florian ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

Author keywords

Amino acid uptake; Erythropoietin; JAK2V617F; Leptin; Tumor cells

Indexed keywords

AMINO ACID TRANSPORTER; BREFELDIN A; CARRIER PROTEIN; JANUS KINASE 2; LEUCINE;

ARTICLE; CELL MEMBRANE; CELL PROLIFERATION; CELL SURVIVAL; CHEMOLUMINESCENCE; HUMAN; MOUSE; NONHUMAN; OOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STIMULATION; TUMOR CELL; UPREGULATION; VOLTAGE CLAMP; XENOPUS;

AMINO ACID TRANSPORT SYSTEMS, NEUTRAL; AMINO ACIDS; ANIMALS; BREFELDIN A; CELL LINE, TUMOR; HUMANS; JANUS KINASE 2; XENOPUS;

EID: 80054905552     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.09.074     Document Type: Article

References (36)

1. Bohmer C., Broer A., Munzinger M., Kowalczuk S., Rasko J.E., Lang F., Broer S. Characterization of mouse amino acid transporter B0AT1 (slc6a19). Biochem. J. 2005, 389:745-751.
2. Broer S., Bailey C.G., Kowalczuk S., Ng C., Vanslambrouck J.M., Rodgers H., Auray-Blais C., Cavanaugh J.A., Broer A., Rasko J.E. Iminoglycinuria and hyperglycinuria are discrete human phenotypes resulting from complex mutations in proline and glycine transporters. J. Clin. Invest. 2008.
3. Broer S. The role of the neutral amino acid transporter B0AT1 (SLC6A19) in Hartnup disorder and protein nutrition. IUBMB. Life 2009, 61:591-599.
4. Verrey F., Singer D., Ramadan T., Vuille-dit-Bille R.N., Mariotta L., Camargo S.M. Kidney amino acid transport. Pflugers Arch. 2009, 458:53-60.
5. Camargo S.M., Singer D., Makrides V., Huggel K., Pos K.M., Wagner C.A., Kuba K., Danilczyk U., Skovby F., Kleta R., Penninger J.M., Verrey F. Tissue-specific amino acid transporter partners ACE2 and collectrin differentially interact with hartnup mutations. Gastroenterology 2009, 136:872-882.
6. Kowalczuk S., Broer A., Tietze N., Vanslambrouck J.M., Rasko J.E., Broer S. A protein complex in the brush-border membrane explains a Hartnup disorder allele. FASEB J. 2008, 22:2880-2887.
7. Cheon C.K., Lee B.H., Ko J.M., Kim H.J., Yoo H.W. Novel mutation in SLC6A19 causing late-onset seizures in Hartnup disorder. Pediatr. Neurol. 2010, 42:369-371.
8. Kleta R., Romeo E., Ristic Z., Ohura T., Stuart C., Arcos-Burgos M., Dave M.H., Wagner C.A., Camargo S.R., Inoue S., Matsuura N., Helip-Wooley A., Bockenhauer D., Warth R., Bernardini I., Visser G., Eggermann T., Lee P., Chairoungdua A., Jutabha P., Babu E., Nilwarangkoon S., Anzai N., Kanai Y., Verrey F., Gahl W.A., Koizumi A. Mutations in SLC6A19, encoding B0AT1, cause Hartnup disorder. Nat. Genet. 2004, 36:999-1002.
9. Seow H.F., Broer S., Broer A., Bailey C.G., Potter S.J., Cavanaugh J.A., Rasko J.E. Hartnup disorder is caused by mutations in the gene encoding the neutral amino acid transporter SLC6A19. Nat. Genet. 2004, 36:1003-1007.
10. Ducroc R., Sakar Y., Fanjul C., Barber A., Bado A., Lostao M.P. Luminal leptin inhibits l-glutamine transport in rat small intestine: involvement of ASCT2 and B0AT1. Am. J. Physiol. Gastrointest. Liver Physiol. 2010, 299:G179-G185.
11. Morris D.L., Rui L. Recent advances in understanding leptin signaling and leptin resistance. Am. J. Physiol. Endocrinol. Metab. 2009, 297:E1247-E1259.
12. Brooks A.J., Waters M.J. The growth hormone receptor: mechanism of activation and clinical implications. Nat. Rev. Endocrinol. 2010, 6:515-525.
13. Spivak J.L. Narrative review: Thrombocytosis, polycythemia vera, and JAK2 mutations: The phenotypic mimicry of chronic myeloproliferation. Ann. Intern. Med. 2010, 152:300-306.
14. Lopez A.F., Hercus T.R., Ekert P., Littler D.R., Guthridge M., Thomas D., Ramshaw H.S., Stomski F., Perugini M., D'Andrea R., Grimbaldeston M., Parker M.W. Molecular basis of cytokine receptor activation. IUBMB Life 2010, 62:509-518.
15. Kurdi M., Booz G.W. JAK redux: a second look at the regulation and role of JAKs in the heart. Am. J. Physiol. Heart Circ. Physiol. 2009, 297:H1545-H1556.
16. Baskin R., Majumder A., Sayeski P.P. The recent medicinal chemistry development of Jak2 tyrosine kinase small molecule inhibitors. Curr. Med. Chem. 2010, 17:4551-4558.
17. Ho K., Valdez F., Garcia R., Tirado C.A. JAK2 Translocations in hematological malignancies: Review of the literature. J. Assoc. Genet. Technol. 2010, 36:107-109.
18. Oh S.T., Gotlib J. JAK2 V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms. Expert. Rev. Hematol. 2010, 3:323-337.
19. Pardanani A., Vannucchi A.M., Passamonti F., Cervantes F., Barbui T., Tefferi A. JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations. Leukemia 2010.
20. Santos F.P., Verstovsek S. JAK2 inhibitors: what's the true therapeutic potential?. Blood Rev. 2010.
21. Tefferi A., Skoda R., Vardiman J.W. Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics. Nat. Rev. Clin. Oncol. 2009, 6:627-637.
22. Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia 2010, 24:1128-1138.
23. Mahfouz R.A., Hoteit R., Salem Z., Bazarbachi A., Mugharbel A., Farhat F., Ziyadeh A., Ibrahim A., Taher A. JAK2 V617F Gene Mutation in the Laboratory Work-Up of Myeloproliferative Disorders: Experience of a Major Referral Center in Lebanon. Genet. Test Mol. Biomarkers 2011.
24. McGivan J.D., Bungard C.I. The transport of glutamine into mammalian cells. Front Biosci. 2007, 12:874-882.
25. Medina M.A. Glutamine and cancer. J. Nutr. 2001, 131:2539S-2542S.
26. Hosseinzadeh Z., Bhavsar S.K., Shojaiefard M., Saxena A., Merches K., Sopjani M., Alesutan I., Lang F. Stimulation of the glucose carrier SGLT1 by JAK2. Biochem. Biophys. Res. Commun. 2011, 408:208-213.
27. Gong T.W., Meyer D.J., Liao J., Hodge C.L., Campbell G.S., Wang X., Billestrup N., Carter-Su C., Schwartz J. Regulation of glucose transport and c-fos and egr-1 expression in cells with mutated or endogenous growth hormone receptors. Endocrinology 1998, 139:1863-1871.
28. Yokota I., Hayashi H., Matsuda J., Saijo T., Naito E., Ito M., Ebina Y., Kuroda Y. Effect of growth hormone on the translocation of GLUT4 and its relation to insulin-like and anti-insulin action. Biochim. Biophys. Acta 1998, 1404:451-456.
29. Bohmer C., Sopjani M., Klaus F., Lindner R., Laufer J., Jeyaraj S., Lang F., Palmada M. The serum and glucocorticoid inducible kinases SGK1-3 stimulate the neutral amino acid transporter SLC6A19. Cell Physiol. Biochem. 2010, 25:723-732.
30. Feng J., Witthuhn B.A., Matsuda T., Kohlhuber F., Kerr I.M., Ihle J.N. Activation of Jak2 catalytic activity requires phosphorylation of Y1007 in the kinase activation loop. Mol. Cell Biol. 1997, 17:2497-2501.
31. Mohamed M.R., Alesutan I., Foller M., Sopjani M., Bress A., Baur M., Salama R.H., Bakr M.S., Mohamed M.A., Blin N., Lang F., Pfister M. Functional analysis of a novel I71N mutation in the GJB2 gene among Southern Egyptians causing autosomal recessive hearing loss. Cell Physiol. Biochem. 2010, 26:959-966.
32. Gehring E.M., Zurn A., Klaus F., Laufer J., Sopjani M., Lindner R., Strutz-Seebohm N., Tavare J.M., Boehmer C., Palmada M., Lang U.E., Seebohm G., Lang F. Regulation of the glutamate transporter EAAT2 by PIKfyve. Cell Physiol. Biochem. 2009, 24:361-368.
33. Rexhepaj R., Dermaku-Sopjani M., Gehring E.M., Sopjani M., Kempe D.S., Foller M., Lang F. Stimulation of electrogenic glucose transport by glycogen synthase kinase 3. Cell Physiol. Biochem. 2010, 26:641-646.
34. Alesutan I.S., Ureche O.N., Laufer J., Klaus F., Zurn A., Lindner R., Strutz-Seebohm N., Tavare J.M., Boehmer C., Palmada M., Lang U.E., Seebohm G., Lang F. Regulation of the glutamate transporter EAAT4 by PIKfyve. Cell Physiol. Biochem. 2010, 25:187-194.
35. Danilczyk U., Sarao R., Remy C., Benabbas C., Stange G., Richter A., Arya S., Pospisilik J.A., Singer D., Camargo S.M., Makrides V., Ramadan T., Verrey F., Wagner C.A., Penninger J.M. Essential role for collectrin in renal amino acid transport. Nature 2006, 444:1088-1091.
36. Lang F., Busch G.L., Ritter M., Volkl H., Waldegger S., Gulbins E., Haussinger D. Functional significance of cell volume regulatory mechanisms. Physiol. Rev. 1998, 78:247-306.